论文部分内容阅读
结直肠癌(colorectal cancer,CRC)是常见的恶性肿瘤,近年来其发病率呈明显上升趋势。以FOLFIRI(氟尿嘧啶、亚叶酸钙和伊立替康)为主的细胞毒性化疗方案对CRC的治疗有显著疗效。贝伐单抗是美国食品药品管理局(Food and Drug Administration,FDA)批准的一线治疗CRC的重组人源化单克隆抗体,其以血管内皮生长因子(vascular endothelial growth factor,VEGF)为靶点,能特异性抑制肿瘤组织血管生成,从而抑制肿瘤组织生长和肿瘤细胞血行转移。本文对贝伐单抗联合标准化疗方案FOLFIRI治疗转移性结直肠癌(metastatic colorectal cancer,mCRC)的疗效和安全性进行简要综述。
Colorectal cancer (CRC) is a common malignant tumor and its incidence has been on the rise in recent years. Cytotoxic chemotherapy regimens dominated by FOLFIRI (fluorouracil, leucovorin and irinotecan) have shown significant efficacy in the treatment of CRC. Bevacizumab is the first-line recombinant humanized monoclonal antibody to CRC approved by the Food and Drug Administration (FDA). Its target is vascular endothelial growth factor (VEGF) Can specifically inhibit tumor angiogenesis, thereby inhibiting tumor growth and tumor cell hematogenous metastasis. This article reviews the efficacy and safety of bevacizumab combined with standard chemotherapy FOLFIRI in the treatment of metastatic colorectal cancer (mCRC).